258 related articles for article (PubMed ID: 21707445)
1. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
Belsey JD
J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
[TBL] [Abstract][Full Text] [Related]
2. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
Zannad F; Fay R
Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
[TBL] [Abstract][Full Text] [Related]
4. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
Mengden T; Uen S; Bramlage P
Vasc Health Risk Manag; 2009; 5():1043-58. PubMed ID: 20057897
[TBL] [Abstract][Full Text] [Related]
5. Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
Zemmrich C; Lüders S; Gansz A; Sturm CD; Fimmers R; Nadal J; Schmieder RE; Schrader J; Bramlage P
J Clin Hypertens (Greenwich); 2013 Nov; 15(11):815-9. PubMed ID: 24102831
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
[TBL] [Abstract][Full Text] [Related]
7. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
8. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Belsey JD
Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
[TBL] [Abstract][Full Text] [Related]
9. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
Neutel J; Shojaee A; Maa JF
Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
[TBL] [Abstract][Full Text] [Related]
11. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
12. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
13. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
15. Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial--rationale and design.
Sakata Y; Nochioka K; Miura M; Takada T; Tadaki S; Miyata S; Shiba N; Shimokawa H
J Cardiol; 2013 Jul; 62(1):31-6. PubMed ID: 23769179
[TBL] [Abstract][Full Text] [Related]
16. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.
Lundkvist J; Ekman M; Kartman B; Carlsson J; Jönsson L; Lithell H
J Hum Hypertens; 2005 Jul; 19(7):569-76. PubMed ID: 15800664
[TBL] [Abstract][Full Text] [Related]
18. Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.
Costa FV
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):265-274. PubMed ID: 28695464
[TBL] [Abstract][Full Text] [Related]
19. Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis.
Mazza A; Sacco AP; Townsend DM; Bregola G; Contatto E; Cappello I; Schiavon L; Ramazzina E; Rubello D
Biomed Pharmacother; 2017 Jun; 90():665-669. PubMed ID: 28415046
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
Ferrario CM; Panjabi S; Buzinec P; Swindle JP
Ther Adv Cardiovasc Dis; 2013 Feb; 7(1):27-39. PubMed ID: 23328188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
